Intravenous colistin sulfate: A rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections

References

• Fridkin S. Increasing prevalence of antimicrobial resistance in intensive care units. Crit Care Med 2001;29:N64–8.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005;40:1333–41.
   PubMed Web of Science ®Google Scholar
• Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, . Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6:589–601.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically—approved standard M7-A7. Wayne, PA, USA: CLSI; 2006.
   Google Scholar
• Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309–32.
   PubMed Web of Science ®Google Scholar
• Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microb Infect 2005;11:15–21.
   Google Scholar
• Ramasubban S, Majumdar A, Das PS. Safety and efficacy of polymyxin B in multidrug resistant Gram-negative severe sepsis and septic shock. Indian J Crit Care Med 2008;12:153–7.
   PubMedGoogle Scholar
• Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hamme SM, . Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 2004;54:566–9.
   PubMed Web of Science ®Google Scholar
• Kasiakou SK, Mchalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005; 49:3136–46.
   PubMed Web of Science ®Google Scholar
• Linden P, Kusne S, Coley K, Fontes P, Kramer D, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003;37:E154–60.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-Wittel IM, . Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003;36:1111–8.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, . Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008;61:417–20.
   PubMed Web of Science ®Google Scholar
• Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, . Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003;7:R78–83.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect 2006;12:1227–30.
   Google Scholar
• Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005;11:115–21.
   PubMed Web of Science ®Google Scholar
• Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, . Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008–11.
   PubMed Web of Science ®Google Scholar
• Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly H, . Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007;33:1162–7.
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methane-sulfonate is an inactive pro-drug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50:1953–8.
   PubMed Web of Science ®Google Scholar
• Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Pharmacokinetics of colistin methanesulpho-nate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004; 53:837–40.
   PubMed Web of Science ®Google Scholar
• Colomycin injection [Summary of product characteristics]. Bexley, UK: Forest Laboratories UK Ltd; 2004.
   Google Scholar
• Coly-Mycin M Parenteral [package insert]. Bristol, TN, USA: Monarch Pharmaceuticals; 2005.
   Google Scholar
• Westerman EM, Le Brun PP, Touw DJ, Frijlink HW, Heijerman HG. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cystic Fibros 2004;3:23–8.
   PubMedGoogle Scholar
• Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005;25:11–25.
   PubMed Web of Science ®Google Scholar
• Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gram-negative bacteria. Antimicrob Agents Chemother 2003;47:2659–62.
   PubMed Web of Science ®Google Scholar
• Pantopoulou A, Giamarellos-Bourboulis EJ, Raftogannis M, Tsaganos T, Dontas I, Koutoukas P, . Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents 2007;29:51–5.
   PubMed Web of Science ®Google Scholar